Current location - Music Encyclopedia - Chinese History - The Development Course of Shanghai Fudan Zhangjiang Biomedical Co., Ltd.
The Development Course of Shanghai Fudan Zhangjiang Biomedical Co., Ltd.
From June 2065438 to June 2005, it is planned to apply to the regulatory authorities of China for listing of A shares, and the estimated investment amount of raised funds is about 97 million yuan.

20 15 In March, there were more than 1000 registered dermatologists of "Photodynamic Technology" in the official account of WeChat, and its exploration in the fields of academic promotion, medical education, medical O2O and other mobile Internet became an industry model.

20 14 12, Fudan Zhangjiang and Zhonghe Houde and other independent third parties jointly established Demei Clinic. Demei Clinic will invest in the establishment and operation of a national chain of skin beauty clinics based on the brand effect and market share of the company in the field of skin beauty in the medical market.

20 14 12, Fudan Zhangjiang acquired Uni Biotechnology.

20 13 12 Shanghai Fudan Zhangjiang Biomedical Co., Ltd. was traded on the main board of Hong Kong, stock code 1349.

20 12 1 1 subsidiary Shanghai traceability biotechnology co., ltd was established.

2011February, Fudan Zhangjiang and Shanghai Pharmaceutical signed a strategic cooperation agreement on innovative drug research and development.

In March 2007, Fudan Zhangjiang registered and established Taizhou Fudan Zhangjiang Pharmaceutical Co., Ltd., a wholly-owned subsidiary in Taizhou, Jiangsu.

In February, 2007, Ala-Ala TM was approved by the US Food and Drug Administration for drug registration and put into the market.

In July 2004, it passed the GMP certification of the US Food and Drug Administration.

In March 2004, the pharmaceutical technology was transferred to overseas enterprises for the first time.

In June 2003, Shanghai Target Pharmaceutical Co., Ltd. held by Fudan Zhangjiang was established.

From June 5438 to February 2002, Shanghai Xianfeng Pharmaceutical Co., Ltd., which Fudan Zhangjiang participated in, was established.

In August 2002, it was listed on Hong Kong Growth Enterprise Market with stock code 823 1.

In July 2002, a brand-new R&D base was completed.

200165438+February to undertake the national high-tech research and development plan (863 plan).

From June 5438 to October 2000 10, it was changed into a joint stock company with the full name of "Shanghai Fudan Zhangjiang Biomedical Co., Ltd.".

In September 2000, China General Technology (Group) Holdings Co., Ltd. acquired the equity and became the second largest shareholder of the company; On February 27th, 20 13, the equity was transferred to Qi Xin Phase II venture capital enterprise.

In March 2000, he undertook the national key scientific and technological project plan.

1In August, 999, Shanghai Pharmaceutical Co., Ltd. (SH600849) acquired the equity and became the largest shareholder of the company.

1999 was approved as "enterprise postdoctoral research mobile station" by the Ministry of Personnel in May.

1998 1 1 was recognized as a "high-tech enterprise" by the Shanghai municipal government.

1998 In August, Shanghai Morgan Tan International Life Science Center Co., Ltd., which is controlled by Shanghai Fudan Zhangjiang Biomedical Co., Ltd., was established.

199765438+In February, Shanghai Zhangjiang Hi-tech Park Development Co., Ltd. (SH600895) increased its capital and became a new shareholder of the company.

1996165438+10 Shanghai Fudan Zhangjiang Biomedical Co., Ltd. was jointly established by Fudan University, Shanghai Pudong New Area Economic and Trade State-owned Assets Management Company and Shanghai Zhangjiang High-tech Development Promotion Center.